Morris AJ, Drinkovi D, Pottumarthy S, MacCulloch D, Kerr AR, West T. Bacteriological outcome after valve surgery for active infective endo- carditis: implications for duration of treatment after surgery. Clin Infect Dis. 2005;41:187 194. doi: 10.1086/430908. 117. Mu oz P, Giannella M, Scoti F, Predomingo M, Puga D, Pinto A, Roda J, Marin M, Bouza E; Group for the Management of Infective Endocarditis of the Gregorio Mara n Hospital (GAME). Two weeks of postsurgi- cal therapy may be enough for high-risk cases of endocarditis caused by Streptococcus viridans or Streptococcus bovis. Clin Microbiol Infect. 2012;18:293 299. doi: 10.1111/j.1469-0691.2011.03594.x. 118. Francioli P, Etienne J, Hoign R, Thys JP, GerberA. Treatment of streptococ- cal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks: efficacy and outpatient treatment feasibility. JAMA. 1992;267:264 267. 119. Wilson WR. Ceftriaxone sodium therapy of penicillin G-susceptible streptococcal endocarditis. JAMA. 1992;267:279 280. 120. Sexton DJ, Tenenbaum MJ, Wilson WR, Steckelberg JM, Tice AD, Gilbert D, Dismukes W, Drew RH, Durack DT. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci: Endocarditis Treatment Consortium Group. Clin Infect Dis. 1998;27:1470 1474. 121. Francioli PB. Ceftriaxone and outpatient treatment of infective endocar- ditis. Infect Dis Clin North Am. 1993;7:97 115. 122. Bickford CL, Spencer AP. Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature. Pharmacotherapy. 2005;25:1389 1395. doi: 10.1592/ phco.2005.25.10.1389. 123. Prabhu RM, Piper KE, Baddour LM, Steckelberg JM, Wilson WR, Patel R. Antimicrobial susceptibility patterns among viridans group strepto- coccal isolates from infective endocarditis patients from 1971 to 1986 and 1994 to 2002. Antimicrob Agents Chemother. 2004;48:4463 4465. doi: 10.1128/AAC.48.11.4463-4465.2004. 124. Knoll B, Tleyjeh IM, Steckelberg JM, Wilson WR, Baddour LM. Infective endocarditis due to penicillin-resistant viridans group strepto- cocci. Clin Infect Dis. 2007;44:1585 1592. doi: 10.1086/518174. 125. Shelburne SA 3rd, Greenberg SB, Aslam S, Tweardy DJ. Successful ceftriaxone therapy of endocarditis due to penicillin non-susceptible viridans streptococci. J Infect. 2007;54:e99 e101. doi: 10.1016/j. jinf.2006.05.010. 126. Fujitani S, Rowlinson MC, George WL. Penicillin G-resistant viridans group streptococcal endocarditis and interpretation of the American Heart Association s guidelines for the treatment of infective endocarditis. Clin Infect Dis. 2008;46:1064 1066. doi: 10.1086/529199. 127. Roberts R. Streptococcal endocarditis: the viridans and beta-hemolytic streptococci. In: Kaye D, ed. Infective Endocarditis. New York, NY: Raven Press; 1992:191 208. 128. Bouvet A, Cremieux AC, Contrepois A, Vallois JM, Lamesch C, Carbon C. Comparison of penicillin and vancomycin, individually and in com- bination with gentamicin and amikacin, in the treatment of experimental endocarditis induced by nutritionally variant streptococci. Antimicrob Agents Chemother. 1985;28:607 611. 129. Lefort A, Mainardi JL, Selton-Suty C, Casassus P, Guillevin L, Lortholary O. Streptococcus pneumoniae endocarditis in adults: a mul- ticenter study in France in the era of penicillin resistance (1991-1998): the Pneumococcal Endocarditis Study Group. Medicine (Baltimore). 2000;79:327 337. 130. Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, Baddour LM, Luna CM, Snydman DR, Ip M, Ko WC, Chedid MB, Andremont A, Klugman KP; International Pneumococcal Study Group. An interna- tional prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis. 2003;37:230 237. doi: 10.1086/377534. 131. Mart nez E, Mir JM, Almirante B, Aguado JM, Fernandez-Viladrich P, Fernandez-Guerrero ML, Villanueva JL, Dronda F, Moreno-Torrico A, Montejo M, Llinares P, Gatell JM; Spanish Pneumococcal Endocarditis Study Group. Effect of penicillin resistance of Streptococcus pneu- moniae on the presentation, prognosis, and treatment of pneumococ- cal endocarditis in adults. Clin Infect Dis. 2002;35:130 139. doi: 10.1086/341024. 132. Smyth EG, Pallett AP, Davidson RN. Group G streptococcal endocardi- tis: two case reports, a review of the literature and recommendations for treatment. J Infect. 1988;16:169 176. 133. Baddour LM. Infective endocarditis caused by beta-hemolytic strepto- cocci: the Infectious Diseases Society of America s Emerging Infections Network. Clin Infect Dis. 1998;26:66 71. 134. LefortA, Lortholary O, Casassus P, Selton-Suty C, Guillevin L, Mainardi JL; -Hemolytic Streptococci Infective Endocarditis Study Group. Comparison between adult endocarditis due to beta-hemolytic strepto- cocci (serogroups A, B, C, and G) and Streptococcus milleri: a multi- center study in France. Arch Intern Med. 2002;162:2450 2456. 135. Sambola A, Miro JM, Tornos MP, Almirante B, Moreno-Torrico A, Gurgui M, Martinez E, Del Rio A, Azqueta M, Marco F, Gatell JM. Streptococcus agalactiae infective endocarditis: analysis of 30 cases and review of the literature, 1962-1998. Clin Infect Dis. 2002;34:1576 1584. doi: 10.1086/340538. 136. Wang A, Athan E, Pappas PA, Fowler VG Jr, Olaison L, Par C, Almirante B, Mu oz P, Rizzi M, Naber C, Logar M, Tattevin P, Iarussi DL, Selton-Suty C, Jones SB, Casab J, Morris A, Corey GR, Cabell CH; International Collaboration on Endocarditis-Prospective Cohort Study Investigators. Contemporary clinical profile and outcome of pros- thetic valve endocarditis. JAMA. 2007;297:1354 1361. doi: 10.1001/ jama.297.12.1354. 137. Chu VH, Woods CW, Miro JM, Hoen B, Cabell CH, Pappas PA, Federspiel J, Athan E, Stryjewski ME, Nacinovich F, Marco F, Levine DP, Elliott TS, Fortes CQ, Tornos P, Gordon DL, Utili R, Delahaye F, Corey GR, Fowler VG Jr; International Collaboration on Endocarditis- Prospective Cohort Study Group. Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. Clin Infect Dis. 2008;46:232 242. doi: 10.1086/524666. 138. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ, Cardo D, Fridkin SK; Vancomycin-Resistant Staphylococcus aureus Investigative Team. Infection with vancomycin-resistant Staphylococcus aureus contain- ing the vanA resistance gene. N Engl J Med. 2003;348:1342 1347. doi: 10.1056/NEJMoa025025. 139. Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, Tenover FC; Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group. Epidemiological and microbiological char- acterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis. 2003;36:429 439. doi: 10.1086/346207. 140. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of van- comycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54:755 771. doi: 10.1093/cid/cir935. 141. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O Sullivan MV, Anderson TL, Roberts SA, Gao W, Christiansen KJ, Coombs GW, Johnson PD, Howden BP. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacte- remia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011;204:340 347. doi: 10.1093/infdis/jir270. 142. Cervera C, Casta eda X, de la Maria CG, del Rio A, Moreno A, Soy D, Pericas JM, Falces C, Armero Y, Almela M, Ninot S, Pare JC, Mestres CA, Gatell JM, Marco F, Miro JM; Hospital Clinic Endocarditis Study Group. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis. Clin Infect Dis. 2014;58:1668 1675. doi: 10.1093/cid/ciu183. 143. Anguera I, Del R o A, Mir JM, Mat nez-Lacasa X, Marco F, Gum JR, Quaglio G, Claramonte X, Moreno A, Mestres CA, Mauri E, Azqueta M, Benito N, Garc a-de la Mar a C, Almela M, Jim nez-Exp sito MJ, Sued O, De Lazzari E, Gatell JM; Hospital Clinic Endocarditis Study Group. Staphylococcus lugdunensis infective endocarditis: description of 10 cases and analysis of native valve, prosthetic valve, and pacemaker Baddour et al Infective Endocarditis in Adults 1481 lead endocarditis clinical profiles. Heart. 2005;91:e10. doi: 10.1136/ hrt.2004.040659. 144. Liu PY, Huang YF, Tang CW, Chen YY, Hsieh KS, Ger LP, Chen YS, Liu YC. Staphylococcus lugdunensis infective endocarditis: a litera- ture review and analysis of risk factors. J Microbiol Immunol Infect. 2010;43:478 484. doi: 10.1016/S1684-1182(10)60074-6. 145. Seenivasan MH, Yu VL. Staphylococcus lugdunensis endocarditis: the hidden peril of coagulase-negative staphylococcus in blood cul- tures. Eur J Clin Microbiol Infect Dis. 2003;22:489 491. doi: 10.1007/ s10096-003-0953-z. 146. Pereira EM, Oliveira FL, Schuenck RP, Zoletti GO, Dos Santos KR. Detection of Staphylococcus lugdunensis by a new species-specific PCR based on the fbl gene. FEMS Immunol Med Microbiol. 2010;58:295 298. doi: 10.1111/j.1574-695X.2009.00626.x. 147. Pinsky BA, Samson D, Ghafghaichi L, Baron EJ, Banaei N. Comparison of real-time PCR and conventional biochemical methods for identifica- tion of Staphylococcus lugdunensis. J Clin Microbiol. 2009;47:3472 3477. doi: 10.1128/JCM.00342-09. 148. Fort n J, Navas E, Mart nez-Beltr n J, P rez-Molina J, Mart n-D vila P, Guerrero A, Moreno S. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glyco- peptides in combination with gentamicin. Clin Infect Dis. 2001;33:120 125. doi: 10.1086/320869. 149. Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW. Initial low- dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009;48:713 721. doi: 10.1086/597031. 150. Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ, Sisson SD, Tidmore WC, vom Eigen KA, Goodman SN, Lietman PS, Petty BG, Flexner C. Oral antibiotic treatment of right-sided staphy- lococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med. 1996;101:68 76. 151. Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with cipro- floxacin and rifampicin. Lancet. 1989;2:1071 1073. 152. Murray HW, Wigley FM, Mann JJ, Arthur RR. Combination antibiotic therapy in staphylococcal endocarditis: the use of methicillin sodium- gentamicin sulfate therapy. Arch Intern Med. 1976;136:480 483. 153. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to paren- teral drugs and in nonaddicts: a prospective study. Ann Intern Med. 1982;97:496 503. 154. McConeghy KW, Bleasdale SC, Rodvold KA. The empirical combina- tion of vancomycin and a -lactam for staphylococcal bacteremia. Clin Infect Dis. 2013;57:1760 1765. doi: 10.1093/cid/cit560. 155. Carugati M, Bayer AS, Mir JM, Park LP, Guimar es AC, Skoutelis A, Fortes CQ, Durante-Mangoni E, Hannan MM, Nacinovich F, Fern ndez- Hidalgo N, Grossi P, Tan RS, Holland T, Fowler VG Jr, Corey RG, Chu VH; International Collaboration on Endocarditis. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the International Collaboration on Endocarditis. Antimicrob Agents Chemother. 2013;57:6213 6222. doi: 10.1128/AAC.01563-13. 156. Dodek P, Phillips P. Questionable history of immediate-type hypersen- sitivity to penicillin in staphylococcal endocarditis: treatment based on skin-test results versus empirical alternative treatment: a decision analy- sis. Clin Infect Dis. 1999;29:1251 1256. doi: 10.1086/313435. 157. Nannini EC, Singh KV, Murray BE. Relapse of type A beta-lactamase- producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin Infect Dis. 2003;37:1194 1198. doi: 10.1086/379021. 158. Watanakunakorn C. Clindamycin therapy of Staphylococcus aureus endocarditis: clinical relapse and development of resistance to clindamy- cin, lincomycin and erythromycin. Am J Med. 1976;60:419 425. 159. Mortara LA, Bayer AS. Staphylococcus aureus bacteremia and endocar- ditis: new diagnostic and therapeutic concepts. Infect Dis Clin North Am. 1993;7:53 68. 160. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of dap- tomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149 2152. doi: 10.1086/430352. 161. Le T, Bayer AS. Combination antibiotic therapy for infective endocardi- tis. Clin Infect Dis. 2003;36:615 621. doi: 10.1086/367661. 162. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52:2463 2467. doi: 10.1128/AAC.00300-08. 163. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med. 1991;115:674 680. 164. Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR; Infectious Diseases Society of America. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56:1 10. doi: 10.1093/cid/ cis966. 165. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim- sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992;117:390 398. doi: 10.7326/0003-4819-117-5-390. 166. Proctor RA. Role of folate antagonists in the treatment of methicillin- resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46:584 593. doi: 10.1086/525536. 167. Steed ME, Vidaillac C, Rybak MJ. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother. 2010;54:5187 5192. doi: 10.1128/ AAC.00536-10. 168. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. Use of antistaphylococcal beta-lactams to increase dapto- mycin activity in eradicating persistent bacteremia due to methicillin- resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53:158 163. doi: 10.1093/cid/cir340. 169. Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, Rosato RR, Rosato AE. -Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother. 2012;56:6192 6200. doi: 10.1128/AAC.01525-12. 170. Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-interme- diate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model [published correction appears in Antimicrob Agents Chemother. 2013;57:1565]. Antimicrob Agents Chemother. 2013;57:66 73. doi: 10.1128/AAC.01586-12. 171. Werth BJ, Vidaillac C, Murray KP, Newton KL, Sakoulas G, Nonejuie P, Pogliano J, Rybak MJ. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin- intermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob Agents Chemother. 2013;57:2376 2379. doi: 10.1128/ AAC.02354-12. 172. Jang HC, Kim SH, Kim KH, Kim CJ, Lee S, Song KH, Jeon JH, Park WB, Kim HB, Park SW, Kim NJ, Kim EC, Oh MD, Choe KW. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bac- teremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis. 2009;49:395 401. doi: 10.1086/600295. 173. Tattevin P, Uhel F, Fily F. Observational studies of salvage treatment for persistent bacteremia: beware of survivor treatment selection bias. Clin Infect Dis. 2009;49:1960; author reply 1961. doi: 10.1086/648500. 174. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treat- ment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58:273 280. doi: 10.1093/jac/ dkl219. 175. Schwalm JD, El-Helou P, Lee CH. Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment. Can J Infect Dis. 2004;15:97 100. 176. Mu oz P, Rodr guez-Creix ms M, Moreno M, Mar n M, Ramallo V, Bouza E; GAME Study Group. Linezolid therapy for infec- tive endocarditis. Clin Microbiol Infect. 2007;13:211 215. doi: 10.1111/j.1469-0691.2006.01585.x. 177. Sander A, Beiderlinden M, Schmid EN, Peters J. Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci. Intensive Care Med. 2002;28:1157 1160. doi: 10.1007/s00134-002-1358-7. 178. Nace H, Lorber B. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin. J Antimicrob Chemother. 2010;65:1315 1316. doi: 10.1093/jac/dkq113. 179. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS 2nd. Methicillin-resistant Staphylococcus aureus bacteraemia and endocar- ditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67:1267 1270. doi: 10.1093/jac/dks006. 180. Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother. 2013;19:42 49. doi: 10.1007/ s10156-012-0449-9. 181. Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ. Large retro- spective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58:2541 2546. doi: 10.1128/AAC.02371-13. 182. Chu VH, Miro JM, Hoen B, Cabell CH, Pappas PA, Jones P, Stryjewski ME, Anguera I, Braun S, Mu oz P, Commerford P, Tornos P, Francis J, Oyonarte M, Selton-Suty C, Morris AJ, Habib G, Almirante B, Sexton DJ, Corey GR, Fowler VG Jr; International Collaboration on Endocarditis-Prospective Cohort Study Group. Coagulase-negative staphylococcal prosthetic valve endocarditis: a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study. Heart. 2009;95:570 576. doi: 10.1136/hrt.2008.152975. 183. Drinkovi D, Morris AJ, Pottumarthy S, MacCulloch D, West T. Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis. J Antimicrob Chemother. 2003;52:820 825. doi: 10.1093/jac/dkg440. 184. Chuard C, Herrmann M, Vaudaux P, Waldvogel FA, Lew DP. Successful therapy of experimental chronic foreign-body infection due to methi- cillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother. 1991;35:2611 2616. 185. Lucet JC, Herrmann M, Rohner P, Auckenthaler R, Waldvogel FA, Lew DP. Treatment of experimental foreign body infection caused by meth- icillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1990;34:2312 2317. 186. John MD, Hibberd PL, Karchmer AW, Sleeper LA, Calderwood SB. Staphylococcus aureus prosthetic valve endocarditis: optimal manage- ment and risk factors for death. Clin Infect Dis. 1998;26:1302 1309. 187. Wilson WR, Geraci JE. Antibiotic treatment of infective endocarditis. Annu Rev Med. 1983;34:413 427. 188. Wilson WR, Karchmer AW, Dajani AS, Taubert KA, Bayer A, Kaye D, Bisno AL, Ferrieri P, Shulman ST, Durack DT. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staph- ylococci, and HACEK microorganisms: American Heart Association. JAMA. 1995;274:1706 1713. 189. Olaison L, Schadewitz K; Swedish Society of Infectious Diseases Quality Assurance Study Group for Endocarditis. Enterococcal endo- carditis in Sweden, 1995-1999: can shorter therapy with aminogly- cosides be used? Clin Infect Dis. 2002;34:159 166. doi: 10.1086/ 338233. 190. Gavald J, Len O, Mir JM, Mu oz P, Montejo M, Alarc n A, de la Torre-Cisneros J, Pe a C, Mart nez-Lacasa X, Sarria C, Bou G, Aguado JM, Navas E, Romeu J, Marco F, Torres C, Tornos P, Planes A, Falc V, Almirante B, PahissaA. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med. 2007;146:574 579. 191. Fern ndez-Hidalgo N, Almirante B, Gavald J, Gurgui M, Pe a C, de Alarc n A, Ruiz J, Vilacosta I, Montejo M, Vallejo N, L pez-Medrano F, Plata A, L pez J, Hidalgo-Tenorio C, G lvez J, S ez C, Lomas JM, Falcone M, de la Torre J, Mart nez-Lacasa X, Pahissa A. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treat- ing Enterococcus faecalis infective endocarditis. Clin Infect Dis. 2013;56:1261 1268. doi: 10.1093/cid/cit052. 192. Chirouze C, Athan E, Alla F, Chu VH, Ralph Corey G, Selton-Suty C, Erpelding ML, Miro JM, Olaison L, Hoen B; International Collaboration on Endocarditis Study Group. Enterococcal endocarditis in the begin- ning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study. Clin Microbiol Infect. 2013;19:1140 1147. doi: 10.1111/1469-0691.12166. 193. Dahl A, Rasmussen RV, Bundgaard H, Hassager C, Bruun LE, Lauridsen TK, Moser C, Sogaard P, Arpi M, Bruun NE. Enterococcus faecalis infective endocarditis: a pilot study of the relationship between dura- tion of gentamicin treatment and outcome. Circulation. 2013;127:1810 1817. doi: 10.1161/CIRCULATIONAHA.112.001170. 194. Geraci JE. The antibiotic therapy of bacterial endocarditis: therapeutic data on 172 patients seen from 1951 through 1957: additional observa- tions on short-term therapy (two weeks) for penicillin-sensitive strepto- coccal endocarditis. Med Clin North Am. 1958;42:1101 1140. 195. Miro JM, Pericas JM, del Rio A; Hospital Clinic Endocarditis Study Group. A new era for treating Enterococcus faecalis endocarditis: ampicillin plus short-course gentamicin or ampicillin plus ceftriaxone: that is the question! Circulation. 2013;127:1763 1766. doi: 10.1161/ CIRCULATIONAHA.113.002431. 196. Wilson WR, Wilkowske CJ, Wright AJ, Sande MA, Geraci JE. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med. 1984;100:816 823. 197. Mandell GL, Kaye D, Levison ME, Hook EW. Enterococcal endocardi- tis: an analysis of 38 patients observed at the NewYork Hospital-Cornell Medical Center. Arch Intern Med. 1970;125:258 264. 198. Brandt CM, Rouse MS, Laue NW, Stratton CW, Wilson WR, Steckelberg JM. Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents. J Infect Dis. 1996;173:909 913. 199. Gavald J, Torres C, Tenorio C, L pez P, Zaragoza M, Capdevila JA, Almirante B, Ruiz F, Borrell N, Gomis X, Pigrau C, Baquero F, Pahissa A. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Antimicrob Agents Chemother. 1999;43:639 646. 200. Arias CA, Contreras GA, Murray BE. Management of multidrug-resis- tant enterococcal infections. Clin Microbiol Infect. 2010;16:555 562. doi: 10.1111/j.1198-743X.2010.03214.x. 201. Kainer MA, Devasia RA, Jones TF, Simmons BP, Melton K, Chow S, Broyles J, Moore KL, Craig AS, Schaffner W. Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg Infect Dis. 2007;13:1024 1030. doi: 10.3201/eid1307.070019. 202. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram- positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36:159 168. doi: 10.1086/345744. 203. Mave V, Garcia-Diaz J, Islam T, Hasbun R. Vancomycin-resistant entero- coccal bacteraemia: is daptomycin as effective as linezolid? J Antimicrob Chemother. 2009;64:175 180. doi: 10.1093/jac/dkp154. 204. Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S. Successful treatment of vancomycin-resistant enterococcus endo- carditis with oral linezolid. Clin Infect Dis. 2001;32:1373 1375. doi: 10.1086/319986. 205. Wareham DW, Abbas H, Karcher AM, Das SS. Treatment of pros- thetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid. J Infect. 2006;52:300 304. doi: 10.1016/j. jinf.2005.05.022. 206. Tsigrelis C, Singh KV, Coutinho TD, Murray BE, Baddour LM. Vancomycin-resistant Enterococcus faecalis endocarditis: linezolid fail- ure and strain characterization of virulence factors. J Clin Microbiol. 2007;45:631 635. doi: 10.1128/JCM.02188-06. 207. Hidron AI, Schuetz AN, Nolte FS, Gould CV, Osborn MK. Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis. J Antimicrob Chemother. 2008;61:1394 1396. doi: 10.1093/jac/dkn105. 208. Levine DP, Lamp KC. Daptomycin in the treatment of patients with infec- tive endocarditis: experience from a registry. Am J Med. 2007;120(suppl 1):S28 S33. doi: 10.1016/j.amjmed.2007.07.011. 209. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy. 2006;26:347 352. doi: 10.1592/ phco.26.3.347. 210. Kanafani ZA, Federspiel JJ, Fowler VG Jr. Infective endocarditis caused by daptomycin-resistant Enterococcus faecalis: a case report. Scand J Infect Dis. 2007;39:75 77. doi: 10.1080/00365540600786465. 211. Schutt AC, Bohm NM. Multidrug-resistant Enterococcus faecium endo- carditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother. 2009;43:2108 2112. doi: 10.1345/aph.1M324. 212. Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. Multicenter study of high-dose daptomycin for treatment of enterococ- cal infections. Antimicrob Agents Chemother. 2013;57:4190 4196. doi: 10.1128/AAC.00526-13. 213. Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomy- cin-resistant Enterococcus isolates in an in vitro pharmacokinetic/phar- macodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2012;56:3174 3180. doi: 10.1128/AAC.06439-11. 214. Sakoulas G, Nonejuie P, Nizet V, Pogliano J, Crum-Cianflone N, Haddad F. Treatment of high-level gentamicin-resistant Enterococcus faeca- lis endocarditis with daptomycin plus ceftaroline. Antimicrob Agents Chemother. 2013;57:4042 4045. doi: 10.1128/AAC.02481-12. Baddour et al Infective Endocarditis in Adults 1483 215. Sakoulas G, Rose W, Nonejuie P, Olson J, Pogliano J, Humphries R, Nizet V. Ceftaroline restores daptomycin activity against dapto- mycin-nonsusceptible vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2014;58:1494 1500. doi: 10.1128/ AAC.02274-13. 216. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA. Ampicillin enhances daptomycin- and cat- ionic host defense peptide-mediated killing of ampicillin- and vanco- mycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2012;56:838 844. doi: 10.1128/AAC.05551-11. 217. Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013;68:2921 2926. doi: 10.1093/jac/dkt294. 218. Geraci JE, Wilson WR. Symposium on infective endocarditis, III: endo- carditis due to Gram-negative bacteria: report of 56 cases. Mayo Clin Proc. 1982;57:145 148. 219. Coburn B, Toye B, Rawte P, Jamieson FB, Farrell DJ, Patel SN. Antimicrobial susceptibilities of clinical isolates of HACEK organ- isms. Antimicrob Agents Chemother. 2013;57:1989 1991. doi: 10.1128/ AAC.00111-13. 220. Chambers ST, Murdoch D, Morris A, Holland D, Pappas P, Almela M, Fern ndez-Hidalgo N, Almirante B, Bouza E, Forno D, del Rio A, Hannan MM, Harkness J, Kanafani ZA, Lalani T, Lang S, Raymond N, Read K, Vinogradova T, Woods CW, Wray D, Corey GR, Chu VH; International Collaboration on Endocarditis Prospective Cohort Study Investigators. HACEK infective endocarditis: characteristics and out- comes from a large, multi-national cohort. PLoS One. 2013;8:e63181. doi: 10.1371/journal.pone.0063181. 221. Morpeth S, Murdoch D, Cabell CH, Karchmer AW, Pappas P, Levine D, Nacinovich F, Tattevin P, Fern ndez-Hidalgo N, Dickerman S, Bouza E, del R o A, Lejko-Zupanc T, de Oliveira Ramos A, Iarussi D, Klein J, Chirouze C, Bedimo R, Corey GR, Fowler VG Jr; International Collaboration on Endocarditis Prospective Cohort Study (ICE-PCS) Investigators. Non-HACEK Gram-negative bacillus endocarditis. Ann Intern Med. 2007;147:829 835. 222. Reyes MP, Reyes KC. Gram-negative endocarditis. Curr Infect Dis Rep. 2008;10:267 274. 223. Hughes CF, Noble N. Vegetectomy: an alternative surgical treatment for infective endocarditis of the atrioventricular valves in drug addicts. J Thorac Cardiovasc Surg. 1988;95:857 861. 224. Arbulu A, Thoms NW, Chiscano A, Wilson RF. Total tricuspid valvulec- tomy without replacement in the treatment of Pseudomonas endocarditis. Surg Forum. 1971;22:162 164. 225. Von Reyn CF, Levy BS, Arbeit RD, Friedland G, Crumpacker CS. Infective endocarditis: an analysis based on strict case definitions. Ann Intern Med. 1981;94(pt 1):505 518. 226. Washington JA. The microbiological diagnosis of infective endocarditis. J Antimicrob Chemother. 1987;20(suppl A):29 39. 227. Werner AS, Cobbs CG, Kaye D, Hook EW. Studies on the bacteremia of bacterial endocarditis. JAMA. 1967;202:199 203. 228. Werner M, Andersson R, Olaison L, Hogevik H. A clinical study of cul- ture-negative endocarditis. Medicine (Baltimore). 2003;82:263 273. doi: 10.1097/01.md.0000085056.63483.d2. 229. Hoen B, Selton-Suty C, Lacassin F, Etienne J, Brian on S, Leport C, Canton P. Infective endocarditis in patients with negative blood cultures: analysis of 88 cases from a one-year nationwide survey in France. Clin Infect Dis. 1995;20:501 506. 230. Berbari EF, Cockerill FR 3rd, Steckelberg JM. Infective endocarditis due to unusual or fastidious microorganisms. Mayo Clin Proc. 1997;72:532 542. doi: 10.1016/S0025-6196(11)63302-8. 231. Pazin GJ, Saul S, Thompson ME. Blood culture positivity: suppression by outpatient antibiotic therapy in patients with bacterial endocarditis. Arch Intern Med. 1982;142:263 268. 232. Tunkel AR, Kaye D. Endocarditis with negative blood cultures. N Engl J Med. 1992;326:1215 1217. doi: 10.1056/NEJM199204303261809. 233. Baron EJ, Miller JM, Weinstein MP, Richter SS, Gilligan PH, Thomson RB Jr, Bourbeau P, Carroll KC, Kehl SC, Dunne WM, Robinson-Dunn B, Schwartzman JD, Chapin KC, Snyder JW, Forbes BA, Patel R, Rosenblatt JE, Pritt BS. A guide to utilization of the microbiology labo- ratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a). Clin Infect Dis. 2013;57:e22 e121. doi: 10.1093/cid/cit278. 234. Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother. 2004;48:1921 1933. doi: 10.1128/AAC.48.6.1921-1933.2004. 235. Thuny F, Fournier PE, Casalta JP, Gouriet F, Lepidi H, Riberi A, Collart F, Habib G, Raoult D. Investigation of blood culture-negative early prosthetic valve endocarditis reveals high prevalence of fungi. Heart. 2010;96:743 747. doi: 10.1136/hrt.2009.181594. 236. Fournier PE, Thuny F, Richet H, Lepidi H, Casalta JP, Arzouni JP, Maurin M, C lard M, Mainardi JL, Caus T, Collart F, Habib G, Raoult D. Comprehensive diagnostic strategy for blood culture-negative endocardi- tis: a prospective study of 819 new cases. Clin Infect Dis. 2010;51:131 140. doi: 10.1086/653675. 237. Geissd rfer W, Moos V, Moter A, Loddenkemper C, Jansen A, Tandler R, Morguet AJ, Fenollar F, Raoult D, Bogdan C, Schneider T. High fre- quency of Tropheryma whipplei in culture-negative endocarditis. J Clin Microbiol. 2012;50:216 222. doi: 10.1128/JCM.05531-11. 238. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involve- ment (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996;93:1579 1587. 239. Kupferwasser LI, Hafner G, Mohr-Kahaly S, Erbel R, Meyer J, Darius H. The presence of infection-related antiphospholipid antibodies in infec- tive endocarditis determines a major risk factor for embolic events. J Am Coll Cardiol. 1999;33:1365 1371. 240. Pierrotti LC, Baddour LM. Fungal endocarditis, 1995-2000. Chest. 2002;122:302 310. 241. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. Fungal endo- carditis: evidence in the world literature, 1965-1995. Clin Infect Dis. 2001;32:50 62. doi: 10.1086/317550. 242. Nguyen MH, Nguyen ML, Yu VL, McMahon D, Keys TF, Amidi M. Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature. Clin Infect Dis. 1996;22:262 267. 243. Baddour LM; Infectious Diseases Society of America s Emerging Infections Network. Long-term suppressive antimicrobial therapy for intravascular device-related infections. Am J Med Sci. 2001;322:209 212. 244. Steinbach WJ, Perfect JR, Cabell CH, Fowler VG, Corey GR, Li JS, Zaas AK, Benjamin DK Jr. A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect. 2005;51:230 247. doi: 10.1016/j. jinf.2004.10.016. 245. Boland JM, Chung HH, Robberts FJ, Wilson WR, Steckelberg JM, Baddour LM, Miller DV. Fungal prosthetic valve endocarditis: Mayo Clinic experience with a clinicopathological analysis. Mycoses. 2011;54:354 360. doi: 10.1111/j.1439-0507.2010.01884.x. 246. Smego RA Jr, Ahmad H. The role of fluconazole in the treatment of Candida endocarditis: a meta-analysis. Medicine (Baltimore). 2011;90:237 249. doi: 10.1097/MD.0b013e3182259d38. 247. Hoen B, Duval X. Clinical practice: infective endocarditis [published correction appears in N Engl J Med. 2013;368:2536]. N Engl J Med. 2013;368:1425 1433. doi: 10.1056/NEJMcp1206782. 248. Delahaye F. Is early surgery beneficial in infective endocarditis? A sys- tematic review. Arch Cardiovasc Dis. 2011;104:35 44. doi: 10.1016/j. acvd.2010.11.003. 249. Tleyjeh IM, Kashour T, Zimmerman V, Steckelberg JM, Wilson WR, Baddour LM. The role of valve surgery in infective endocarditis man- agement: a systematic review of observational studies that included pro- pensity score analysis. Am Heart J. 2008;156:901 909. doi: 10.1016/j. ahj.2008.06.031. 250. Desch S, Freund A, de Waha S, Eitel I, Lurz P, Stiermaier T, Fuernau G, Schuler G, Thiele H. Outcome in patients with left-sided native- valve infective endocarditis and isolated large vegetations. Clin Cardiol. 2014;37:626 633. doi: 10.1002/clc.22315. 251. Chirouze C,Alla F, FowlerVG Jr, Sexton DJ, Corey GR, ChuVH,WangA, Erpelding ML, Durante-Mangoni E, Fern ndez-Hidalgo N, Giannitsioti E, Hannan MM, Lejko-Zupanc T, Mir JM, Mu oz P, Murdoch DR, Tattevin P, Tribouilloy C, Hoen B; ICE Prospective Investigators. Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study. Clin Infect Dis. 2015;60:741 749. doi: 10.1093/cid/ciu871. 252. Karchmer AW, Bayer AS. Editorial commentary: surgical therapy for Staphylococcus aureus prosthetic valve endocarditis: proceed with cau- tion (caveat emptor). Clin Infect Dis. 2015;60:750 752. doi: 10.1093/ cid/ciu877. 253. Vikram HR, Buenconsejo J, Hasbun R, Quagliarello VJ. Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis. JAMA. 2003;290:3207 3214. doi: 10.1001/jama.290.24.3207. 254. Aksoy O, Sexton DJ, Wang A, Pappas PA, Kourany W, Chu V, Fowler VG Jr, Woods CW, Engemann JJ, Corey GR, Harding T, Cabell CH. Early surgery in patients with infective endocarditis: a propensity score analysis. Clin Infect Dis. 2007;44:364 372. doi: 10.1086/510583. 255. Cabell CH, Abrutyn E, Fowler VG Jr, Hoen B, Miro JM, Corey GR, Olaison L, Pappas P, Anstrom KJ, Stafford JA, Eykyn S, Habib G, Mestres CA, Wang A; International Collaboration on Endocarditis Merged Database (ICE-MD) Study Group Investigators. Use of surgery in patients with native valve infective endocarditis: results from the International Collaboration on Endocarditis Merged Database. Am Heart J. 2005;150:1092 1098. doi: 10.1016/j.ahj.2005.03.057. 256. Wang A, Pappas P, Anstrom KJ, Abrutyn E, Fowler VG Jr, Hoen B, Miro JM, Corey GR, Olaison L, Stafford JA, Mestres CA, Cabell CH; International Collaboration on Endocarditis Investigators. The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort. Am Heart J. 2005;150:1086 1091. doi: 10.1016/j.ahj.2005.01.023. 257. van Walraven C, Davis D, Forster AJ, Wells GA. Time-dependent bias was common in survival analyses published in leading clini- cal journals. J Clin Epidemiol. 2004;57:672 682. doi: 10.1016/j. jclinepi.2003.12.008. 258. Tleyjeh IM, Ghomrawi HM, Steckelberg JM, Montori VM, Hoskin TL, Enders F, Huskins WC, Mookadam F, Wilson WR, Zimmerman V, Baddour LM. Conclusion about the association between valve surgery and mortality in an infective endocarditis cohort changed after adjusting for survivor bias. J Clin Epidemiol. 2010;63:130 135. doi: 10.1016/j. jclinepi.2008.06.022. 259. Lalani T, Chu VH, Park LP, Cecchi E, Corey GR, Durante-Mangoni E, Fowler VG Jr, Gordon D, Grossi P, Hannan M, Hoen B, Mu oz P, Rizk H, Kanj SS, Selton-Suty C, Sexton DJ, Spelman D, Ravasio V, Tripodi MF, WangA; International Collaboration on Endocarditis Prospective Cohort Study Investigators. In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis [published correction appears in JAMA Intern Med. 2013;173:1846]. JAMA Intern Med. 2013;173:1495 1504. doi: 10.1001/jamainternmed. 2013.8203. 260. Gaca JG, Sheng S, Daneshmand MA, O Brien S, Rankin JS, Brennan JM, Hughes GC, Glower DD, Gammie JS, Smith PK. Outcomes for endocarditis surgery in North America: a simplified risk scoring sys- tem. J Thorac Cardiovasc Surg. 2011;141:98 106.e1 e2. doi: 10.1016/j. jtcvs.2010.09.016. 261. Botelho-Nevers E, Thuny F, Casalta JP, Richet H, Gouriet F, Collart F, Riberi A, Habib G, Raoult D. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med. 2009;169:1290 1298. doi: 10.1001/ archinternmed.2009.192. 262. Tleyjeh IM, Steckelberg JM, Georgescu G, Ghomrawi HM, Hoskin TL, Enders FB, Mookadam F, Huskins WC, Wilson WR, Baddour LM. The association between the timing of valve surgery and 6-month mortal- ity in left-sided infective endocarditis [published correction appears hrt.2007.118968. 263. Musci M, Siniawski H, Pasic M, Grauhan O, Weng Y, Meyer R, Yankah CA, Hetzer R. Surgical treatment of right-sided active infective endocar- ditis with or without involvement of the left heart: 20-year single center experience. Eur J Cardiothorac Surg. 2007;32:118 125. doi: 10.1016/j. ejcts.2007.02.034. 264. Akinosoglou K, Apostolakis E, Koutsogiannis N, Leivaditis V, Gogos CA. Right-sided infective endocarditis: surgical management. Eur J Cardiothorac Surg. 2012;42:470 479. doi: 10.1093/ejcts/ezs084. 265. Maruyama M, Kuriyama Y, Sawada T, Yamaguchi T, Fujita T, Omae T. Brain damage after open heart surgery in patients with acute cardioem- bolic stroke. Stroke. 1989;20:1305 1310. 266. GillinovAM, Shah RV, Curtis WE, Stuart RS, Cameron DE, Baumgartner WA, Greene PS. Valve replacement in patients with endocarditis and acute neurologic deficit. Ann Thorac Surg. 1996;61:1125 1129. 267. Eishi K, Kawazoe K, Kuriyama Y, Kitoh Y, Kawashima Y, Omae T. Surgical management of infective endocarditis associated with cere- bral complications: multi-center retrospective study in Japan. J Thorac Cardiovasc Surg. 1995;110:1745 1755. 268. Cooper HA, Thompson EC, Laureno R, Fuisz A, Mark AS, Lin M, Goldstein SA. Subclinical brain embolization in left-sided infective endocarditis: results from the Evaluation by MRI of the Brains of Patients With Left-Sided Intracardiac Solid Masses (EMBOLISM) pilot study. Circulation. 2009;120:585 591. doi: 10.1161/CIRCULATIONAHA. 108.834432. 269. Hosono M, SasakiY, Hirai H, Sakaguchi M, NakahiraA, Seo H, Morisaki A, Suehiro S. Considerations in timing of surgical intervention for infec- tive endocarditis with cerebrovascular complications. J Heart Valve Dis. 2010;19:321 325. 270. Ruttmann E, Willeit J, Ulmer H, Chevtchik O, H fer D, Poewe W, Laufer G, M ller LC. Neurological outcome of septic cardioembolic stroke after infective endocarditis. Stroke. 2006;37:2094 2099. doi: 10.1161/01. STR.0000229894.28591.3f. 271. Snygg-Martin U, Gustafsson L, Rosengren L, Alsi A, Ackerholm P, Andersson R, Olaison L. Cerebrovascular complications in patients with left-sided infective endocarditis are common: a prospective study using magnetic resonance imaging and neurochemical brain damage markers. Clin Infect Dis. 2008;47:23 30. doi: 10.1086/588663. 272. Thuny F, Avierinos JF, Tribouilloy C, Giorgi R, Casalta JP, Milandre L, Brahim A, Nadji G, Riberi A, Collart F, Renard S, Raoult D, Habib G. Impact of cerebrovascular complications on mortality and neuro- logic outcome during infective endocarditis: a prospective multicen- tre study. Eur Heart J. 2007;28:1155 1161. doi: 10.1093/eurheartj/ ehm005. 273. Barsic B, Dickerman S, Krajinovic V, Pappas P, Altclas J, Carosi G, Casab JH, Chu VH, Delahaye F, Edathodu J, Fortes CQ, Olaison L, Pangercic A, Patel M, Rudez I, Tamin SS, Vincelj J, Bayer AS, Wang A; International Collaboration on Endocarditis Prospective Cohort Study Investigators. Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. Clin Infect Dis. 2013;56:209 217. doi: 10.1093/cid/cis878. R, Noureddine M, PlataA, Lomas JM, G lvez-Acebal J, Hidalgo-Tenorio C, Ru z-Morales J, Mart nez-Marcos FJ, Reguera JM, de la Torre-Lima J, deAlarc n Gonz lezA; Group for the Study of Cardiovascular Infections of the Andalusian Society of Infectious Diseases; Spanish Network for Research in Infectious Diseases. Neurological complications of infec- tive endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. Circulation. 2013;127:2272 2284. doi: 10.1161/CIRCULATIONAHA.112.000813. 275. Lutas EM, Roberts RB, Devereux RB, Prieto LM. Relation between the presence of echocardiographic vegetations and the complication rate in infective endocarditis. Am Heart J. 1986;112:107 113. 276. De Castro S, Magni G, Beni S, Cartoni D, Fiorelli M, Venditti M, Schwartz SL, Fedele F, Pandian NG. Role of transthoracic and trans- esophageal echocardiography in predicting embolic events in patients with active infective endocarditis involving native cardiac valves. Am J Cardiol. 1997;80:1030 1034. 277. Heiro M, Nikoskelainen J, Engblom E, Kotilainen E, Marttila R, Kotilainen P. Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland. Arch Intern Med. 2000;160:2781 2787. 278. Vilacosta I, Graupner C, San Rom n JA, Sarri C, Ronderos R, Fern ndez C, Mancini L, Sanz O, Sanmart n JV, Stoermann W. Risk of embolization after institution of antibiotic therapy for infective endocarditis. J Am Coll Cardiol. 2002;39:1489 1495. 279. Deleted in proof. 280. Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, Doco-Lecompte T, Eisen DP, Fortes CQ, Fowler VG Jr, Lerakis S, Miro JM, Pappas P, Peterson GE, Rubinstein E, Sexton DJ, Suter F, Tornos P, Verhagen DW, Cabell CH; ICE Investigators. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J. 2007;154:1086 1094. doi: 10.1016/j. ahj.2007.07.023. 281. Thuny F, Di Salvo G, Belliard O, Avierinos JF, Pergola V, Rosenberg V, Casalta JP, Gouvernet J, Derumeaux G, Iarussi D, Ambrosi P, Calabr R, Calabro R, Riberi A, Collart F, Metras D, Lepidi H, Raoult D, Harle JR, Weiller PJ, Cohen A, Habib G. Risk of embolism and death in infec- tive endocarditis: prognostic value of echocardiography: a prospec- tive multicenter study [published correction appears in Circulation. CIRCULATIONAHA.104.493155. 282. Alsip SG, Blackstone EH, Kirklin JW, Cobbs CG. Indications for car- diac surgery in patients with active infective endocarditis. Am J Med. 1985;78:138 148. Baddour et al Infective Endocarditis in Adults 1485 283. Di Salvo G, Habib G, Pergola V, Avierinos JF, Philip E, Casalta JP, Vailloud JM, Derumeaux G, Gouvernet J, Ambrosi P, Lambert M, Ferracci A, Raoult D, Luccioni R. Echocardiography predicts embolic events in infective endocarditis. J Am Coll Cardiol. 2001;37:1069 1076. 284. Chu VH, Cabell CH, Benjamin DK Jr, Kuniholm EF, Fowler VG Jr, Engemann J, Sexton DJ, Corey GR, Wang A. Early predictors of in-hos- pital death in infective endocarditis. Circulation. 2004;109:1745 1749. doi: 10.1161/01.CIR.0000124719.61827.7F. 285. Salem DN, Daudelin HD, Levine HJ, Pauker SG, Eckman MH, Riff J. Antithrombotic therapy in valvular heart disease. Chest. 2001;119(suppl):207S 219S. 286. Tornos P, Almirante B, Mirabet S, Permanyer G, Pahissa A, Soler-Soler J. Infective endocarditis due to Staphylococcus aureus: deleterious effect of anticoagulant therapy. Arch Intern Med. 1999;159:473 475. 287. Kupferwasser LI, Yeaman MR, Nast CC, Kupferwasser D, Xiong YQ, Palma M, Cheung AL, Bayer AS. Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J Clin Invest. 2003;112:222 233. doi: 10.1172/ JCI16876. 288. Chan KL, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, Turek MA, Robinson TI, Moher D; Investigators of the Multicenter Aspirin Study in Infective Endocarditis. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll Cardiol. 2003;42:775 780. 289. Kupferwasser LI,Yeaman MR, Shapiro SM, Nast CC, Sullam PM, Filler SG, Bayer AS. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. Circulation. 1999;99:2791 2797. 290. Anavekar NS, Tleyjeh IM, Anavekar NS, Mirzoyev Z, Steckelberg JM, Haddad C, Khandaker MH,WilsonWR, Chandrasekaran K, Baddour LM. Impact of prior antiplatelet therapy on risk of embolism in infective endo- carditis [published correction appears in Clin Infect Dis. 2007;44:1398]. Clin Infect Dis. 2007;44:1180 1186. doi: 10.1086/513197. 291. Chan KL, Tam J, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, Turek M, Robinson T, Williams K. Effect of long-term aspirin use on embolic events in infective endocarditis. Clin Infect Dis. 2008;46:37 41. doi: 10.1086/524021. 292. Eisen DP, Corey GR, McBryde ES, Fowler VG Jr, Miro JM, Cabell CH, Street AC, Paiva MG, Ionac A, Tan RS, Tribouilloy C, Pachirat O, Jones SB, Chipigina N, Naber C, Pan A, Ravasio V, Gattringer R, Chu VH, Bayer AS; ICE Investigators. Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiv- ing acetyl-salicylic acid. J Infect. 2009;58:332 338. doi: 10.1016/j. jinf.2009.03.006. 293. Pepin J, Tremblay V, Bechard D, Rodier F, Walker C, Dufresne D, Lafontaine A, Li N, Lacroix C, Lanthier L. Chronic antiplatelet therapy and mortality among patients with infective endocarditis. Clin Microbiol Infect. 2009;15:193 199. doi: 10.1111/j.1469-0691. 2008.02665.x. 294. Snygg-Martin U, Rasmussen RV, Hassager C, Bruun NE, Andersson R, Olaison L. The relationship between cerebrovascular complica- tions and previously established use of antiplatelet therapy in left- sided infective endocarditis. Scand J Infect Dis. 2011;43:899 904. doi: 10.3109/00365548.2011.603742. 295. Anavekar NS, Schultz JC, De Sa DD, Thomas JM, Lahr BD, Tleyjeh IM, Steckelberg JM, Wilson WR, Baddour LM. Modifiers of symptomatic embolic risk in infective endocarditis [published correction appears in Mayo Clin Proc. 2012;87:309]. Mayo Clin Proc. 2011;86:1068 1074. doi: 10.4065/mcp.2011.0111. 296. Omari B, Shapiro S, Ginzton L, Robertson JM, Ward J, Nelson RJ, Bayer AS. Predictive risk factors for periannular extension of native valve endocarditis: clinical and echocardiographic analyses. Chest. 1989;96:1273 1279. 297. Middlemost S, Wisenbaugh T, Meyerowitz C, Teeger S, Essop R, Skoularigis J, Cronje S, Sareli P. A case for early surgery in native left- sided endocarditis complicated by heart failure: results in 203 patients. J Am Coll Cardiol. 1991;18:663 667. 298. Blumberg EA, Karalis DA, Chandrasekaran K, Wahl JM, Vilaro J, Covalesky VA, Mintz GS. Endocarditis-associated paravalvular abscesses: do clinical parameters predict the presence of abscess? Chest. 1995;107:898 903. 299. Becher H, Hanrath P, Bleifeld W, Bleese N. Correlation of echocardio- graphic and surgical findings in acute bacterial endocarditis. Eur Heart J. 1984;5(suppl C):67 70. 300. Arnett EN, Roberts WC. Prosthetic valve endocarditis: clinicopathologic analysis of 22 necropsy patients with comparison observations in 74 nec- ropsy patients with active infective endocarditis involving natural left- sided cardiac valves. Am J Cardiol. 1976;38:281 292. 301. Fernicola DJ, Roberts WC. Frequency of ring abscess and cuspal infec- tion in active infective endocarditis involving bioprosthetic valves. Am J Cardiol. 1993;72:314 323. 302. Carpenter JL. Perivalvular extension of infection in patients with infec- tious endocarditis. Rev Infect Dis. 1991;13:127 138. 303. Anguera I, Miro JM, Vilacosta I, Almirante B, Anguita M, Mu oz P, Roman JA, de Alarcon A, Ripoll T, Navas E, Gonzalez-Juanatey C, Cabell CH, Sarria C, Garcia-Bolao I, Fari as MC, Leta R, Rufi G, Miralles F, Pare C, Evangelista A, Fowler VG Jr, Mestres CA, de Lazzari E, Guma JR; Aorto-cavitary Fistula in Endocarditis Working Group. Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. Eur Heart J. 2005;26:288 297. doi: 10.1093/eurheartj/ehi034. 304. Daniel W, Schroder E, Nonast-Daniel B, Lichtlen P. Conventional and transoesophageal echocardiography in the diagnosis of infective endo- carditis. Eur Heart J. 1987;8:287 292. 305. Leung DY, Cranney GB, Hopkins AP, Walsh WF. Role of transoesopha- geal echocardiography in the diagnosis and management of aortic root abscess. Br Heart J. 1994;72:175 181. 306. Rohmann S, Seifert T, Erbel R, Jakob H, Mohr-Kahaly S, Makowski T, G rge G, Oelert H, Meyer J. Identification of abscess formation in native-valve infective endocarditis using transesophageal echocardiog- raphy: implications for surgical treatment. Thorac Cardiovasc Surg. 1991;39:273 280. doi: 10.1055/s-2007-1019985. 307. Kunis RL, Sherrid MV, McCabe JB, Grieco MH, Dwyer EM Jr. Successful medical therapy of mitral anular abscess complicating infec- tive endocarditis. J Am Coll Cardiol. 1986;7:953 955. 308. Vlessis AA, Hovaguimian H, Jaggers J, Ahmad A, Starr A. Infective endocarditis: ten-year review of medical and surgical therapy. Ann Thorac Surg. 1996;61:1217 1222. 309. Mullany CJ, Chua YL, Schaff HV, Steckelberg JM, Ilstrup DM, Orszulak TA, Danielson GK, Puga FJ. Early and late survival after sur- gical treatment of culture-positive active endocarditis. Mayo Clin Proc. 1995;70:517 525. doi: 10.1016/S0025-6196(11)64307-3. 310. Glazier JJ, Verwilghen J, Donaldson RM, Ross DN. Treatment of complicated prosthetic aortic valve endocarditis with annular abscess formation by homograft aortic root replacement. J Am Coll Cardiol. 1991;17:1177 1182. 311. Ross D. Allograft root replacement for prosthetic endocarditis. J Card Surg. 1990;5:68 72. 312. McGiffin DC, Galbraith AJ, McLachlan GJ, Stower RE, Wong ML, Stafford EG, Gardner MA, Pohlner PG, O Brien MF. Aortic valve infec- tion: risk factors for death and recurrent endocarditis after aortic valve replacement. J Thorac Cardiovasc Surg. 1992;104:511 520. 313. Walkes JC, Reardon MJ. Current thinking in stentless valve surgery. Curr Opin Cardiol. 2003;18:117 123. 314. Chun CH, Raff MJ, Contreras L, Varghese R, Waterman N, Daffner R, Melo JC. Splenic abscess. Medicine (Baltimore). 1980;59:50 65. 315. Bohmfalk GL, Story JL, Wissinger JP, Brown WE Jr. Bacterial intracra- nial aneurysm. J Neurosurg. 1978;48:369 382. 316. WilsonWR, Giuliani ER, Danielson GK, Geraci JE. Management of com- plications of infective endocarditis. Mayo Clin Proc. 1982;57:162 170. 317. Camarata PJ, Latchaw RE, R fenacht DA, Heros RC. Intracranial aneu- rysms. Invest Radiol. 1993;28:373 382. 318. Lerner PI. Neurologic complications of infective endocarditis. Med Clin North Am. 1985;69:385 398. 319. Clare CE, Barrow DL. Infectious intracranial aneurysms. Neurosurg Clin N Am. 1992;3:551 566. 320. Moskowitz MA, Rosenbaum AE, Tyler HR. Angiographically monitored resolution of cerebral mycotic aneurysms. Neurology. 1974;24:1103 1108. 321. Huston J 3rd, Nichols DA, Luetmer PH, Goodwin JT, Meyer FB, Wiebers DO, Weaver AL. Blinded prospective evaluation of sensitivity of MR angiography to known intracranial aneurysms: importance of aneurysm size. AJNR Am J Neuroradiol. 1994;15:1607 1614. 322. Wilson WR, Bower TC, Creager MA, Amin-Hanjani S, O Gara PT, Lockhart PB, Darouiche RO, Ramlawi B, Derdeyn CP, Bolger AF, Levison ME, Taubert KA, Baltimore RS, Baddour LM; on behalf of the American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Surgery and Anesthesia, Council on Peripheral Vascular Disease, and Stroke Council. Vascular graft infections, mycotic aneu- rysms, and endovascular infections: a scientific statement from the American Heart Association. Circulation. In press. 323. Tice AD. Safety of outpatient parenteral antimicrobial therapy for endo- carditis. Clin Infect Dis. 2002;34:419 420. doi: 10.1086/324369. 324. Monteiro CA, Cobbs CG. Outpatient management of infective endocar- ditis. Curr Infect Dis Rep. 2001;3:319 327. 325. Tice AD, Rehm SJ, Dalovisio JR, Bradley JS, Martinelli LP, Graham DR, Gainer RB, Kunkel MJ, Yancey RW, Williams DN; IDSA. Practice guidelines for outpatient parenteral antimicrobial therapy: IDSA guidelines. Clin Infect Dis. 2004;38:1651 1672. doi: 10.1086/420939. 326. Andrews MM, von Reyn CF. Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infec- tive endocarditis. Clin Infect Dis. 2001;33:203 209. doi: 10.1086/321814. 327. Lockhart PB, Brennan MT, Thornhill M, Michalowicz BS, Noll J, Bahrani-Mougeot FK, Sasser HC. Poor oral hygiene as a risk fac- tor for infective endocarditis-related bacteremia. J Am Dent Assoc. 2009;140:1238 1244. 328. Lockhart PB. Antibiotic prophylaxis for dental procedures: are we drilling in the wrong direction? Circulation. 2012;126:11 12. doi: 10.1161/CIRCULATIONAHA.112.115204.